A phase III, randomized, controlled, open-label, multicentre, three arm study to compare the efficacy and safety of a dual-boosted HIV-1 protease inhibitor regimen of fosamprenavir/lopinavir/ritonavir 1400mg/533mg/133mg twice daily and an increased dosage regimen of FPV [fosamprenavir]/RTV [ritonavir] 1400mg/100mg BID [bidaily] versus the standard dosage regimen of FPV/RTV 700mg/100mg BID for 24 weeks in multiple-PI [protease inhibitor] experienced, HIV-infected adults experiencing virological failure

Trial Profile

A phase III, randomized, controlled, open-label, multicentre, three arm study to compare the efficacy and safety of a dual-boosted HIV-1 protease inhibitor regimen of fosamprenavir/lopinavir/ritonavir 1400mg/533mg/133mg twice daily and an increased dosage regimen of FPV [fosamprenavir]/RTV [ritonavir] 1400mg/100mg BID [bidaily] versus the standard dosage regimen of FPV/RTV 700mg/100mg BID for 24 weeks in multiple-PI [protease inhibitor] experienced, HIV-infected adults experiencing virological failure

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Fosamprenavir (Primary) ; Lopinavir/ritonavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms TRIAD
  • Most Recent Events

    • 01 Aug 2009 Results published in the Journal of Antimicrobial Chemotherapy.
    • 09 Nov 2007 Status changed from recruiting to discontinued. This study has been terminated due to incomplete data.
    • 17 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top